CANCER:

Lung Cancer

News alerts, weekly reports and conference planners

No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	lurbinectedin Sensitive: A1 - Approval Pharmamar Press Release - 4 days (New A1) lurbinectedin Sensitive : A1 Pharmamar Press Release - 4d	lurbinectedin Sensitive: A1 - Approval Pharmamar Press Release - 4 days lurbinectedin Sensitive : A1 Pharmamar Press Release - 4 days - (New A1)
EGFR T263P + EGFR L858R + MET amplification	Non Small Cell Lung Cancer	EGFR T263P + EGFR L858R + MET amplification	Non Small Cell Lung Cancer	erlotinib + capmatinib Sensitive: C4 – Case Studies Front Oncol - 4 days (New C4) erlotinib + capmatinib Sensitive : C4 Front Oncol - 4d	erlotinib + capmatinib Sensitive: C4 – Case Studies Front Oncol - 4 days erlotinib + capmatinib Sensitive : C4 Front Oncol - 4 days - (New C4)
KRAS mutation + KMT2C mutation	Non Small Cell Lung Cancer	KRAS mutation + KMT2C mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Onco Targets Ther - 6 days (New C3) Immunotherapy Sensitive : C3 Onco Targets Ther - 6d	Immunotherapy Sensitive: C3 – Early Trials Onco Targets Ther - 6 days Immunotherapy Sensitive : C3 Onco Targets Ther - 6 days - (New C3)
STRN-ALK fusion	Lung Adenocarcinoma	STRN-ALK fusion	Lung Adenocarcinoma	ensartinib Sensitive: C4 – Case Studies Curr Oncol - 6 days (New C4) ensartinib Sensitive : C4 Curr Oncol - 6d	ensartinib Sensitive: C4 – Case Studies Curr Oncol - 6 days ensartinib Sensitive : C4 Curr Oncol - 6 days - (New C4)
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	toripalimab Sensitive: A1 - Approval GlobeNewswire - 1 week (New A1) toripalimab Sensitive : A1 GlobeNewswire - 1wk	toripalimab Sensitive: A1 - Approval GlobeNewswire - 1 week toripalimab Sensitive : A1 GlobeNewswire - 1 week - (New A1)
EPHA5 mutation	Non Small Cell Lung Cancer	EPHA5 mutation	Non Small Cell Lung Cancer	atezolizumab Resistant: C3 – Early Trials BMC Pulm Med - 1 week (New C3) atezolizumab Resistant : C3 BMC Pulm Med - 1wk	atezolizumab Resistant: C3 – Early Trials BMC Pulm Med - 1 week atezolizumab Resistant : C3 BMC Pulm Med - 1 week - (New C3)
CCDC85A-ALK fusion	Lung Adenocarcinoma	CCDC85A-ALK fusion	Lung Adenocarcinoma	alectinib Sensitive: C4 – Case Studies J Cell Mol Med - 1 week (New C4) alectinib Sensitive : C4 J Cell Mol Med - 1wk	alectinib Sensitive: C4 – Case Studies J Cell Mol Med - 1 week alectinib Sensitive : C4 J Cell Mol Med - 1 week - (New C4)
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	atezolizumab Sensitive: C3 – Early Trials Nat Med - 2 weeks (New C3) atezolizumab Sensitive : C3 Nat Med - 2wk	atezolizumab Sensitive: C3 – Early Trials Nat Med - 2 weeks atezolizumab Sensitive : C3 Nat Med - 2 weeks - (New C3)
ALK rearrangement + PD-L1 overepxression	Non Small Cell Lung Cancer	ALK rearrangement + PD-L1 overepxression	Non Small Cell Lung Cancer	ALK inhibitor Resistant: C3 – Early Trials Front Immunol - 2 weeks (New C3) ALK inhibitor Resistant : C3 Front Immunol - 2wk	ALK inhibitor Resistant: C3 – Early Trials Front Immunol - 2 weeks ALK inhibitor Resistant : C3 Front Immunol - 2 weeks - (New C3)
ALK rearrangement + CTLA4 overexpression	Non Small Cell Lung Cancer	ALK rearrangement + CTLA4 overexpression	Non Small Cell Lung Cancer	ALK inhibitor Resistant: C3 – Early Trials Front Immunol - 2 weeks (New C3) ALK inhibitor Resistant : C3 Front Immunol - 2wk	ALK inhibitor Resistant: C3 – Early Trials Front Immunol - 2 weeks ALK inhibitor Resistant : C3 Front Immunol - 2 weeks - (New C3)
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	atezolizumab Sensitive: C3 – Early Trials Nat Med - 2 weeks (New C3) atezolizumab Sensitive : C3 Nat Med - 2wk	atezolizumab Sensitive: C3 – Early Trials Nat Med - 2 weeks atezolizumab Sensitive : C3 Nat Med - 2 weeks - (New C3)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression	Lung Adenocarcinoma	EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression	Lung Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies Lung Cancer - 2 weeks (New C4) pembrolizumab Sensitive : C4 Lung Cancer - 2wk	pembrolizumab Sensitive: C4 – Case Studies Lung Cancer - 2 weeks pembrolizumab Sensitive : C4 Lung Cancer - 2 weeks - (New C4)
CD74-NRG1 fusion + EGFR mutation + HER-2 mutation	Lung Adenocarcinoma	CD74-NRG1 fusion + EGFR mutation + HER-2 mutation	Lung Adenocarcinoma	afatinib + pyrotinib Sensitive: C4 – Case Studies Thorac Cancer - 2 weeks (New C4) afatinib + pyrotinib Sensitive : C4 Thorac Cancer - 2wk	afatinib + pyrotinib Sensitive: C4 – Case Studies Thorac Cancer - 2 weeks afatinib + pyrotinib Sensitive : C4 Thorac Cancer - 2 weeks - (New C4)
STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	durvalumab + CP-675206 Resistant: B - Late Trials ESMO 2022 - 3 weeks (New B) durvalumab + CP-675206 Resistant : B ESMO 2022 - 3wk	durvalumab + CP-675206 Resistant: B - Late Trials ESMO 2022 - 3 weeks durvalumab + CP-675206 Resistant : B ESMO 2022 - 3 weeks - (New B)
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : B ESMO 2022 - 3wk	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials ESMO 2022 - 3 weeks sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : B ESMO 2022 - 3 weeks - (New B)
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks (New B) atezolizumab Sensitive : B Cancer Med - 3wk	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks atezolizumab Sensitive : B Cancer Med - 3 weeks - (New B)
ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks (New B) atezolizumab Sensitive : B Cancer Med - 3wk	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks atezolizumab Sensitive : B Cancer Med - 3 weeks - (New B)
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	durvalumab + CP-675206 Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) durvalumab + CP-675206 Sensitive : B ESMO 2022 - 3wk	durvalumab + CP-675206 Sensitive: B - Late Trials ESMO 2022 - 3 weeks durvalumab + CP-675206 Sensitive : B ESMO 2022 - 3 weeks - (New B)
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	durvalumab + CP-675206 Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) durvalumab + CP-675206 Sensitive : B ESMO 2022 - 3wk	durvalumab + CP-675206 Sensitive: B - Late Trials ESMO 2022 - 3 weeks durvalumab + CP-675206 Sensitive : B ESMO 2022 - 3 weeks - (New B)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	brigatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) brigatinib Sensitive : C3 ESMO 2022 - 3wk	brigatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks brigatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BRAF mutation	Non Small Cell Lung Cancer	BRAF mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials Cancers (Basel) - 3 weeks (New C3) PD1 inhibitor Sensitive : C3 Cancers (Basel) - 3wk	PD1 inhibitor Sensitive: C3 – Early Trials Cancers (Basel) - 3 weeks PD1 inhibitor Sensitive : C3 Cancers (Basel) - 3 weeks - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials Cancers (Basel) - 3 weeks (New C3) PD-L1 inhibitor Sensitive : C3 Cancers (Basel) - 3wk	PD-L1 inhibitor Sensitive: C3 – Early Trials Cancers (Basel) - 3 weeks PD-L1 inhibitor Sensitive : C3 Cancers (Basel) - 3 weeks - (New C3)
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	afatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) afatinib Sensitive : C3 ESMO 2022 - 3wk	afatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks afatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	sintilimab Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) sintilimab Sensitive : C3 BMC Cancer - 3wk	sintilimab Sensitive: C3 – Early Trials BMC Cancer - 3 weeks sintilimab Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	osimertinib + tepotinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) osimertinib + tepotinib Sensitive : C3 ESMO 2022 - 3wk	osimertinib + tepotinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks osimertinib + tepotinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
RB1 wild-type	Small Cell Lung Cancer	RB1 wild-type	Small Cell Lung Cancer	nivolumab Sensitive: C3 – Early Trials JCO Precis Oncol - 3 weeks (New C3) nivolumab Sensitive : C3 JCO Precis Oncol - 3wk	nivolumab Sensitive: C3 – Early Trials JCO Precis Oncol - 3 weeks nivolumab Sensitive : C3 JCO Precis Oncol - 3 weeks - (New C3)
HER-2 amplification	Lung Cancer	HER-2 amplification	Lung Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ESMO 2022 - 3wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks trastuzumab + pertuzumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KN046 Sensitive : C3 ESMO 2022 - 3wk	KN046 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks KN046 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KN046 Sensitive : C3 ESMO 2022 - 3wk	KN046 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks KN046 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	BPI-7711 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) BPI-7711 Sensitive : C3 ESMO 2022 - 3wk	BPI-7711 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks BPI-7711 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	pralsetinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) pralsetinib Sensitive : C3 ESMO 2022 - 3wk	pralsetinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks pralsetinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation + MET overexpression	Non Small Cell Lung Cancer	MET exon 14 mutation + MET overexpression	Non Small Cell Lung Cancer	capmatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) capmatinib Sensitive : C3 ESMO 2022 - 3wk	capmatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks capmatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation + ALK wild-type	Non Small Cell Lung Cancer	MET exon 14 mutation + ALK wild-type	Non Small Cell Lung Cancer	capmatinib + PDR001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) capmatinib + PDR001 Sensitive : C3 ESMO 2022 - 3wk	capmatinib + PDR001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks capmatinib + PDR001 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation + EGFR wild-type	Non Small Cell Lung Cancer	MET exon 14 mutation + EGFR wild-type	Non Small Cell Lung Cancer	capmatinib + PDR001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) capmatinib + PDR001 Sensitive : C3 ESMO 2022 - 3wk	capmatinib + PDR001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks capmatinib + PDR001 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 G778_P780dup	Non Small Cell Lung Cancer	HER-2 G778_P780dup	Non Small Cell Lung Cancer	HM 78136B Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) HM 78136B Sensitive : C3 ESMO 2022 - 3wk	HM 78136B Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks HM 78136B Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3wk	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3wk	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3wk	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) pembrolizumab + ramucirumab Sensitive : C3 ESMO 2022 - 3wk	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks pembrolizumab + ramucirumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) pembrolizumab + ramucirumab Sensitive : C3 ESMO 2022 - 3wk	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks pembrolizumab + ramucirumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KIT mutation	Non Small Cell Lung Cancer	KIT mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Resistant : C3 ESMO 2022 - 3wk	Immunotherapy Resistant: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	CKD-702 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) CKD-702 Sensitive : C3 ESMO 2022 - 3wk	CKD-702 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks CKD-702 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR mutation + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) bevacizumab + atezolizumab Sensitive : C3 ESMO 2022 - 3wk	bevacizumab + atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks bevacizumab + atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EML4-ALK fusion + ALK positive	Non Small Cell Lung Cancer	EML4-ALK fusion + ALK positive	Non Small Cell Lung Cancer	brigatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) brigatinib Sensitive : C3 ESMO 2022 - 3wk	brigatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks brigatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	alectinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) alectinib Sensitive : C3 ESMO 2022 - 3wk	alectinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks alectinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C + ATM wild-type	Non Small Cell Lung Cancer	KRAS G12C + ATM wild-type	Non Small Cell Lung Cancer	KRAS inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KRAS inhibitor Resistant : C3 ESMO 2022 - 3wk	KRAS inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks KRAS inhibitor Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C + SMARCA4 wild-type	Non Small Cell Lung Cancer	KRAS G12C + SMARCA4 wild-type	Non Small Cell Lung Cancer	KRAS inhibitor Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KRAS inhibitor Sensitive : C3 ESMO 2022 - 3wk	KRAS inhibitor Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks KRAS inhibitor Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
RET positive + SMARCA4 mutation	Non Small Cell Lung Cancer	RET positive + SMARCA4 mutation	Non Small Cell Lung Cancer	RET inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) RET inhibitor Resistant : C3 ESMO 2022 - 3wk	RET inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks RET inhibitor Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
RET positive + KRAS G12V	Non Small Cell Lung Cancer	RET positive + KRAS G12V	Non Small Cell Lung Cancer	RET inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) RET inhibitor Resistant : C3 ESMO 2022 - 3wk	RET inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks RET inhibitor Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 20 insertion + TP53 mutation	Non Small Cell Lung Cancer	EGFR exon 20 insertion + TP53 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET amplification + MET overexpression	Non Small Cell Lung Cancer	MET amplification + MET overexpression	Non Small Cell Lung Cancer	REGN5093 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) REGN5093 Sensitive : C3 ESMO 2022 - 3wk	REGN5093 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks REGN5093 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	REGN5093 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) REGN5093 Sensitive : C3 ESMO 2022 - 3wk	REGN5093 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks REGN5093 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CYP4B1 expression	Lung Cancer	CYP4B1 expression	Lung Cancer	Immunotherapy Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Resistant : C3 ESMO 2022 - 3wk	Immunotherapy Resistant: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
CLEC3B overexpression	Non Small Cell Lung Cancer	CLEC3B overexpression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 18 mutation + EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 18 mutation + EGFR exon 21 mutation	Non Small Cell Lung Cancer	afatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) afatinib Sensitive : C3 ESMO 2022 - 3wk	afatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks afatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-L1 underexpression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 underexpression	Lung Non-Squamous Non-Small Cell Cancer	MEDI5752 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) MEDI5752 Sensitive : C3 ESMO 2022 - 3wk	MEDI5752 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks MEDI5752 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	lazertinib + ABN401 Sensitive: D – Preclinical ESMO 2022 - 3 weeks (New D) lazertinib + ABN401 Sensitive : D ESMO 2022 - 3wk	lazertinib + ABN401 Sensitive: D – Preclinical ESMO 2022 - 3 weeks lazertinib + ABN401 Sensitive : D ESMO 2022 - 3 weeks - (New D)
EGFR C797S + EGFR T790M + EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR C797S + EGFR T790M + EGFR exon 19 deletion	Non Small Cell Lung Cancer	JIN-A02 Sensitive: D – Preclinical ESMO 2022 - 3 weeks (New D) JIN-A02 Sensitive : D ESMO 2022 - 3wk	JIN-A02 Sensitive: D – Preclinical ESMO 2022 - 3 weeks JIN-A02 Sensitive : D ESMO 2022 - 3 weeks - (New D)
EGFR C797S + EGFR T790M + EGFR L858R	Non Small Cell Lung Cancer	EGFR C797S + EGFR T790M + EGFR L858R	Non Small Cell Lung Cancer	JIN-A02 Sensitive: D – Preclinical ESMO 2022 - 3 weeks (New D) JIN-A02 Sensitive : D ESMO 2022 - 3wk	JIN-A02 Sensitive: D – Preclinical ESMO 2022 - 3 weeks JIN-A02 Sensitive : D ESMO 2022 - 3 weeks - (New D)
EGFR mutation + CDCA3 underexpression	Non Small Cell Lung Cancer	EGFR mutation + CDCA3 underexpression	Non Small Cell Lung Cancer	osimertinib Resistant: D – Preclinical ESMO 2022 - 3 weeks (New D) osimertinib Resistant : D ESMO 2022 - 3wk	osimertinib Resistant: D – Preclinical ESMO 2022 - 3 weeks osimertinib Resistant : D ESMO 2022 - 3 weeks - (New D)
EGFR mutation + CDCA3 underexpression	Non Small Cell Lung Cancer	EGFR mutation + CDCA3 underexpression	Non Small Cell Lung Cancer	erlotinib Resistant: D – Preclinical ESMO 2022 - 3 weeks (New D) erlotinib Resistant : D ESMO 2022 - 3wk	erlotinib Resistant: D – Preclinical ESMO 2022 - 3 weeks erlotinib Resistant : D ESMO 2022 - 3 weeks - (New D)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval AstraZeneca Press Release - 4 weeks (New A1) osimertinib Sensitive : A1 AstraZeneca Press Release - 4wk	osimertinib Sensitive: A1 - Approval AstraZeneca Press Release - 4 weeks osimertinib Sensitive : A1 AstraZeneca Press Release - 4 weeks - (New A1)
EGFR wild-type	Lung Non-Small Cell Squamous Cancer	EGFR wild-type	Lung Non-Small Cell Squamous Cancer	cemiplimab Sensitive: B - Late Trials Nat Med - 4 weeks (New B) cemiplimab Sensitive : B Nat Med - 4wk	cemiplimab Sensitive: B - Late Trials Nat Med - 4 weeks cemiplimab Sensitive : B Nat Med - 4 weeks - (New B)
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	cemiplimab Sensitive: B - Late Trials Nat Med - 4 weeks (New B) cemiplimab Sensitive : B Nat Med - 4wk	cemiplimab Sensitive: B - Late Trials Nat Med - 4 weeks cemiplimab Sensitive : B Nat Med - 4 weeks - (New B)
ROS1 wild-type	Lung Non-Small Cell Squamous Cancer	ROS1 wild-type	Lung Non-Small Cell Squamous Cancer	cemiplimab Sensitive: B - Late Trials Nat Med - 4 weeks (New B) cemiplimab Sensitive : B Nat Med - 4wk	cemiplimab Sensitive: B - Late Trials Nat Med - 4 weeks cemiplimab Sensitive : B Nat Med - 4 weeks - (New B)
ROS1 wild-type	Lung Non-Squamous Non-Small Cell Cancer	ROS1 wild-type	Lung Non-Squamous Non-Small Cell Cancer	cemiplimab Sensitive: B - Late Trials Nat Med - 4 weeks (New B) cemiplimab Sensitive : B Nat Med - 4wk	cemiplimab Sensitive: B - Late Trials Nat Med - 4 weeks cemiplimab Sensitive : B Nat Med - 4 weeks - (New B)
ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	cemiplimab Sensitive: B - Late Trials Nat Med - 4 weeks (New B) cemiplimab Sensitive : B Nat Med - 4wk	cemiplimab Sensitive: B - Late Trials Nat Med - 4 weeks cemiplimab Sensitive : B Nat Med - 4 weeks - (New B)
ALK wild-type	Lung Non-Small Cell Squamous Cancer	ALK wild-type	Lung Non-Small Cell Squamous Cancer	cemiplimab Sensitive: B - Late Trials Nat Med - 4 weeks (New B) cemiplimab Sensitive : B Nat Med - 4wk	cemiplimab Sensitive: B - Late Trials Nat Med - 4 weeks cemiplimab Sensitive : B Nat Med - 4 weeks - (New B)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials J Cancer Res Clin Oncol - 4 weeks (New C3) EGFR inhibitor Sensitive : C3 J Cancer Res Clin Oncol - 4wk	EGFR inhibitor Sensitive: C3 – Early Trials J Cancer Res Clin Oncol - 4 weeks EGFR inhibitor Sensitive : C3 J Cancer Res Clin Oncol - 4 weeks - (New C3)
HER-2 amplification	Non Small Cell Lung Cancer	HER-2 amplification	Non Small Cell Lung Cancer	rivoceranib + pyrotinib Sensitive: C3 – Early Trials BMC Med - 4 weeks (New C3) rivoceranib + pyrotinib Sensitive : C3 BMC Med - 4wk	rivoceranib + pyrotinib Sensitive: C3 – Early Trials BMC Med - 4 weeks rivoceranib + pyrotinib Sensitive : C3 BMC Med - 4 weeks - (New C3)
EML4-ALK variant 1	Non Small Cell Lung Cancer	EML4-ALK variant 1	Non Small Cell Lung Cancer	crizotinib Sensitive: C3 – Early Trials Eur J Cancer - 4 weeks (New C3) crizotinib Sensitive : C3 Eur J Cancer - 4wk	crizotinib Sensitive: C3 – Early Trials Eur J Cancer - 4 weeks crizotinib Sensitive : C3 Eur J Cancer - 4 weeks - (New C3)
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	ALK inhibitor Sensitive: C3 – Early Trials Medicine (Baltimore) - 4 weeks (New C3) ALK inhibitor Sensitive : C3 Medicine (Baltimore) - 4wk	ALK inhibitor Sensitive: C3 – Early Trials Medicine (Baltimore) - 4 weeks ALK inhibitor Sensitive : C3 Medicine (Baltimore) - 4 weeks - (New C3)
BRAF mutation	Non Small Cell Lung Cancer	BRAF mutation	Non Small Cell Lung Cancer	trametinib + dabrafenib Sensitive: C3 – Early Trials ISPOR-EU 2022 - 4 weeks (New C3) trametinib + dabrafenib Sensitive : C3 ISPOR-EU 2022 - 4wk	trametinib + dabrafenib Sensitive: C3 – Early Trials ISPOR-EU 2022 - 4 weeks trametinib + dabrafenib Sensitive : C3 ISPOR-EU 2022 - 4 weeks - (New C3)
EGFR mutation + UBXN11 mutation	Non Small Cell Lung Cancer	EGFR mutation + UBXN11 mutation	Non Small Cell Lung Cancer	erlotinib Resistant: C3 – Early Trials J Clin Oncol - 4 weeks (New C3) erlotinib Resistant : C3 J Clin Oncol - 4wk	erlotinib Resistant: C3 – Early Trials J Clin Oncol - 4 weeks erlotinib Resistant : C3 J Clin Oncol - 4 weeks - (New C3)
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	BPI-7711 Sensitive: C3 – Early Trials J Thorac Oncol - 4 weeks (New C3) BPI-7711 Sensitive : C3 J Thorac Oncol - 4wk	BPI-7711 Sensitive: C3 – Early Trials J Thorac Oncol - 4 weeks BPI-7711 Sensitive : C3 J Thorac Oncol - 4 weeks - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	Angiogenesis inhibitor Sensitive: C3 – Early Trials Sci Rep - 4 weeks (New C3) Angiogenesis inhibitor Sensitive : C3 Sci Rep - 4wk	Angiogenesis inhibitor Sensitive: C3 – Early Trials Sci Rep - 4 weeks Angiogenesis inhibitor Sensitive : C3 Sci Rep - 4 weeks - (New C3)
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	rivoceranib + pyrotinib Sensitive: C3 – Early Trials BMC Med - 4 weeks (New C3) rivoceranib + pyrotinib Sensitive : C3 BMC Med - 4wk	rivoceranib + pyrotinib Sensitive: C3 – Early Trials BMC Med - 4 weeks rivoceranib + pyrotinib Sensitive : C3 BMC Med - 4 weeks - (New C3)
SLC8A1-ALK fusion	Lung Adenocarcinoma	SLC8A1-ALK fusion	Lung Adenocarcinoma	ceritinib Sensitive: C4 – Case Studies Medicine (Baltimore) - 4 weeks (New C4) ceritinib Sensitive : C4 Medicine (Baltimore) - 4wk	ceritinib Sensitive: C4 – Case Studies Medicine (Baltimore) - 4 weeks ceritinib Sensitive : C4 Medicine (Baltimore) - 4 weeks - (New C4)
EGFR exon 21 mutation	Lung Adenocarcinoma	EGFR exon 21 mutation	Lung Adenocarcinoma	dacomitinib Sensitive: C4 – Case Studies Medicine (Baltimore) - 4 weeks (New C4) dacomitinib Sensitive : C4 Medicine (Baltimore) - 4wk	dacomitinib Sensitive: C4 – Case Studies Medicine (Baltimore) - 4 weeks dacomitinib Sensitive : C4 Medicine (Baltimore) - 4 weeks - (New C4)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib Sensitive: A1 - Approval sotorasib Sensitive : A1	sotorasib Sensitive: A1 - Approval sotorasib Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	tepotinib Sensitive: A1 - Approval tepotinib Sensitive : A1	tepotinib Sensitive: A1 - Approval tepotinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	capmatinib Sensitive: A1 - Approval capmatinib Sensitive : A1	capmatinib Sensitive: A1 - Approval capmatinib Sensitive : A1
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	cemiplimab Sensitive: A1 - Approval cemiplimab Sensitive : A1	cemiplimab Sensitive: A1 - Approval cemiplimab Sensitive : A1
RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1

Lung Cancer

Associations(3250)

Associations
(3250)